1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63988E5F0FA1CED940025869A003DEB1D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/3988E5F0FA1CED940025869A003DEB1D?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Influences on Market Entry

Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media

ID: 5672


Features:

8 Info Graphics

20 Data Graphics

440+ Metrics

6 Narratives


Pages/Slides: 34


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Disease Awareness Program Excellence: Utilizing Advocacy Groups and Social Media”

STUDY OVERVIEW

Disease state awareness campaigns allow pharma companies to inform patients and HCPs about new trends in particular disease states/therapeutic areas. These unbranded campaigns also set the table for future marketing efforts for a product launch.

Patient advocacy groups and social media are two conduits that pharma companies use to both gather and disseminate information on current disease state trends.

Best Practices, LLC conducted this benchmarking research to spotlight effective practices around the utilization of advocacy groups and social media for disease awareness programs. This study will serve as a reference point for pharmaceutical leaders to compare against their disease awareness programs.

KEY TOPICS

  • Involvement of advocacy groups in disease awareness
  • Involvement of legal department in disease awareness
  • Use of social media for disease awareness

KEY METRICS
  • Please rate the importance – from a disease awareness program perspective - of the listed patient advocacy group activities and support services
  • Which approaches work best to support disease awareness activities with patient advocacy groups?
  • Please indicate the disease awareness activities you utilize with advocacy groups, when you first use each activity, and whether you use that activity in the subsequent periods listed
  • What level of involvement does your organization's legal department take in each of the listed disease awareness program areas?
  • Please indicate disease awareness activities you conduct on social media, when you first initiate each activity, and whether you use that activity in the subsequent periods listed
  • Please indicate, in order, your three most heavily used social media activities to generate disease awareness
  • Please indicate your total overall level (raw amount) of investment in social media disease awareness activities during the last fiscal year
  • Please indicate the percentage that social media spending represents of your total overall disease awareness budget

SAMPLE KEY FINDINGS
  • Social Media:
    • Continually monitor and modify social medical activities
    • Message boards and moderators provide great direct feedback to manufacturers

METHODOLOGY

Best Practices, LLC engaged 30 leaders from 28 top life sciences organizations in this benchmarking research. Four executives participated in deep-dive operational interviews. Secondary research is occasionally provided for context.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Public Relations; Chemical; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; AstraZeneca; Bayer; Biogen; Catalyst Pharmaceuticals; CSL Behring; Daiichi Sankyo; Eli Lilly and Company; EMD Serono; FleishmanHillard; Fresenius Medical Care; Genentech; Genzyme; Indivior; Merck KGaA; Merck Sharp & Dohme; Myovant Sciences; Nevakar; NexGen Healthcare; Novartis; Prometheus Laboratories; PruGen Pharmaceuticals; Sanofi; Teva Pharmaceutical Industries Ltd; Tokai Pharmaceuticals; Vertex Pharmaceuticals; ZS Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.